Adegramotide

Adegramotide is an investigational peptide cancer vaccine derived from the Wilms tumor 1 (WT1) protein, a WT1-specific CD4-positive T-cell epitope of 18 amino acids with an embedded CD8-positive T-cell epitope. It is one of the two peptide components of DSP-7888 Emulsion, a therapeutic cancer vaccine emulsified in the Montanide ISA 51 adjuvant, where it is paired with （nelatimotide）, a 19-amino-acid peptide carrying two WT1 CD8 epitopes. The vaccine is administered intradermally and has been tested in higher-risk myelodysplastic syndrome after azacitidine failure, where 78.7 percent of patients mounted a WT1-specific immune reaction, and in recurrent glioblastoma in combination with bevacizumab. Adegramotide's role is to supply helper T-cell help that augments the cytotoxic response, a division of labour established in preclinical work. The compound has no approved indication in any jurisdiction.阿德格拉莫肽（adegramotide）是一种在研多肽癌症疫苗，源自 Wilms 肿瘤 1（WT1）蛋白，是 18 个氨基酸的 WT1 特异性 CD4 阳性 T 细胞表位，内嵌一个 CD8 阳性 T 细胞表位。它是 DSP-7888 乳剂的两种多肽组分之一，该治疗性癌症疫苗以 Montanide ISA 51 佐剂乳化，与其配对的是 （nelatimotide）——一种携带两个 WT1 CD8 表位的 19 氨基酸多肽。该疫苗皮内给药，已在阿扎胞苷失败后的高危骨髓增生异常综合征中测试（78.7% 的患者产生 WT1 特异性免疫反应），并在复发胶质母细胞瘤中与贝伐珠单抗联用测试。阿德格拉莫肽的作用是提供增强细胞毒性应答的辅助性 T 细胞帮助，这一分工在临床前工作中确立。该化合物未在任何司法管辖区获批。

History and development

• WT1 is a zinc-finger transcription factor that is among the most frequently overexpressed proteins in human cancer, with high expression in acute myeloid leukaemia, myelodysplastic syndromes and many solid tumours, while its expression in normal adults is largely confined to the kidney and the gonads. That restricted normal-tissue profile, combined with essential roles in leukaemic cells, made WT1 one of the most attractive cancer antigens for vaccine development. Unlike mutated neoepitopes, WT1 is a shared self-antigen, so vaccines against it must overcome tolerance rather than simply recognize foreign material. Decades of immunology work established that WT1-specific T cells can be raised in patients and that they recognize WT1-expressing tumour cells in an HLA-restricted manner.WT1 是一种锌指转录因子，是人类癌症中表达最频繁过表达的蛋白之一，在急性髓系白血病、骨髓增生异常综合征与许多实体瘤中高表达，而正常成人中的表达主要限于肾与性腺。这一受限的正常组织特征，加上在白血病细胞中的必需作用，使 WT1 成为疫苗开发最具吸引力的癌症抗原之一。与突变新表位不同，WT1 是共享的自身抗原，因此针对它的疫苗必须克服耐受而非简单识别异物。数十年的免疫学工作确立了 WT1 特异性 T 细胞可在患者中激发，并以 HLA 限制方式识别表达 WT1 的肿瘤细胞。
• Sumitomo Dainippon Pharma, now known as Sumitomo Pharma, designed DSP-7888 Emulsion around a two-peptide concept: （nelatimotide）, a 19-amino-acid peptide composed of two WT1-specific CD8-positive T-cell epitopes, and adegramotide, an 18-amino-acid WT1-specific CD4-positive T-cell epitope with an embedded CD8 epitope. The rationale for including both arms came from preclinical observation: cytotoxic T cells induced by a CD8-only peptide vaccine failed to become activated when co-cultured with tumour cells, even in the presence of anti-PD-1, whereas cells induced by the complete emulsion did become activated. Helper T-cell support, in other words, was not optional decoration but a functional requirement for the cytotoxic arm to work inside an immunosuppressive tumour microenvironment. Adegramotide is the molecule that supplies that help.住友制药（Sumitomo Dainippon Pharma，现名 Sumitomo Pharma）围绕双多肽概念设计 DSP-7888 乳剂：（nelatimotide） 是由两个 WT1 特异性 CD8 阳性 T 细胞表位组成的 19 氨基酸多肽，阿德格拉莫肽则是 18 氨基酸的 WT1 特异性 CD4 阳性 T 细胞表位，内嵌一个 CD8 表位。同时纳入两臂的理由来自临床前观察：仅含 CD8 表位的肽疫苗诱导的细胞毒性 T 细胞与肿瘤细胞共培养时无法激活，即使有抗 PD-1 存在也是如此，而完整乳剂诱导的细胞却能激活。换言之，辅助性 T 细胞支持不是可有可无的点缀，而是细胞毒性臂在免疫抑制性肿瘤微环境中发挥作用的功能必需。阿德格拉莫肽正是提供这种帮助的分子。^[1]
• The peptide lengths were chosen deliberately. The developers' work showed that delivering longer peptides, around 20 amino acids, rather than the classical short 9-mer epitopes minimizes a specific failure mode of cutaneous peptide vaccines: short peptides can be captured and retained at the injection site together with cytotoxic T cells, suppressing their antitumour potential. Montanide ISA 51, the water-in-oil adjuvant in the emulsion, stabilizes the vaccine peptides and slows their systemic release, giving dendritic cells and macrophages time to arrive and take up antigen. The combination of long peptides and a depot adjuvant is the formulation logic of DSP-7888 Emulsion, and adegramotide's 18 residues sit at the centre of that design.肽长是刻意选择的。开发者的工作显示，递送约 20 个氨基酸的较长肽段而非经典 9 聚体短表位，可最小化皮肤肽疫苗的一个特定失败模式：短肽可与细胞毒性 T 细胞一起在注射部位被捕获滞留，抑制其抗肿瘤潜力。乳剂中的水油佐剂 Montanide ISA 51 稳定疫苗肽并减缓其系统释放，让树突状细胞与巨噬细胞有时间抵达并摄取抗原。长肽加储库佐剂的组合是 DSP-7888 乳剂的处方逻辑，阿德格拉莫肽的 18 个残基正位于该设计中心。
• The first clinical readout came from a phase 1/2 study in patients with higher-risk myelodysplastic syndrome who had failed prior azacitidine treatment, a population with few options after hypomethylating-agent failure. Intradermal DSP-7888 Emulsion was well tolerated in that study, and 78.7 percent of patients experienced a positive WT1-specific immune reaction, defined as a delayed-type hypersensitivity response or WT1-specific CD8-positive T-cell positivity. Patients with a positive immune reaction experienced significantly longer overall survival than those without one, an association that echoes the broader cancer-vaccine experience of correlating immune response with outcome. The study remains the programme's clearest clinical signal.首个临床读数来自一项在阿扎胞苷治疗失败的高危骨髓增生异常综合征患者中开展的 1/2 期研究，该人群在去甲基化药物失败后选择寥寥。皮内给予 DSP-7888 乳剂在该研究中耐受良好，78.7% 的患者出现阳性 WT1 特异性免疫反应，定义为延迟型超敏反应阳性或 WT1 特异性 CD8 阳性 T 细胞阳性。出现阳性免疫反应的患者总生存显著长于无反应者，这一关联呼应了癌症疫苗领域将免疫应答与结局相关的更广义经验。该研究仍是该项目最清晰的临床信号。^[1]
• The programme then extended into solid tumours with a phase 3 study, registered as NCT03149003, in patients with recurrent or progressive glioblastoma treated after resection, combining the vaccine with bevacizumab. The trial enrolled 221 patients and evaluates progression-free and overall survival, positioning DSP-7888 Emulsion as a partner to anti-angiogenic therapy rather than as a stand-alone agent. Earlier glioblastoma work had shown the vaccine was well tolerated with no dose-limiting toxicities and induced higher levels of WT1-specific cytotoxic lymphocytes. The choice of glioblastoma reflects both the poor prognosis of recurrent disease and WT1's documented expression in these tumours.该项目随后以一项注册号为 NCT03149003 的 3 期研究扩展到实体瘤，对象为切除术后复发或进展的胶质母细胞瘤患者，疫苗与贝伐珠单抗联用。该试验入组 221 例患者，评价无进展生存与总生存，把 DSP-7888 乳剂定位为抗血管生成治疗的伙伴而非独立药物。早期胶质母细胞瘤工作显示该疫苗耐受良好、无剂量限制毒性，并诱导更高水平的 WT1 特异性细胞毒性淋巴细胞。选择胶质母细胞瘤既反映复发疾病的恶劣预后，也反映 WT1 在这些肿瘤中的已有表达记录。

Medical uses

• Adegramotide has no approved use in any jurisdiction, and its clinical testing is confined to the DSP-7888 Emulsion programme. The lead indication under study is higher-risk myelodysplastic syndrome after failure of azacitidine, where the phase 1/2 study demonstrated immunogenicity and an immune-response-associated survival difference. The phase 3 programme addresses recurrent or progressive glioblastoma, where the vaccine is combined with bevacizumab at 10 mg/kg intravenously every two weeks. In both settings the vaccine is given intradermally, weekly for the first five doses, then every two weeks for doses six through fifteen, and every four weeks thereafter. No dose outside the trial setting exists.阿德格拉莫肽未在任何司法管辖区获批，其临床测试仅限于 DSP-7888 乳剂项目。研究中的主要适应症是阿扎胞苷失败后的高危骨髓增生异常综合征，1/2 期研究证明了免疫原性及免疫应答相关生存差异。3 期项目针对复发或进展的胶质母细胞瘤，疫苗与每两周 10 mg/kg 静脉给药的贝伐珠单抗联用。两种情境下疫苗均皮内给药，前五剂每周一次，第六至十五剂每两周一次，此后每四周一次。试验情境之外不存在剂量。
• Patient selection in the vaccine programme is HLA-dependent: WT1-specific cytotoxic lymphocytes are induced in patients carrying HLA-A02:01, HLA-A02:06 or HLA-A24:02, the alleles that present the relevant epitopes, and the glioblastoma studies enrolled these populations. That restriction is a defining practical feature of peptide vaccines against shared self-antigens, and it limits the addressable population to roughly defined subsets in each country. The helper epitope carried by adegramotide broadens the response within those HLA types by supplying CD4 help, but it does not remove the HLA restriction itself. No HLA-agnostic formulation has been developed.疫苗项目中的患者选择依赖 HLA：WT1 特异性细胞毒性淋巴细胞在携带 HLA-A02:01、HLA-A02:06 或 HLA-A24:02（呈递相关表位的等位基因）的患者中诱导，胶质母细胞瘤研究入组的正是这些人群。这一限制是靶向共享自身抗原的肽疫苗的决定性实践特征，它把可及人群限定为每个国家中大致定义的亚群。阿德格拉莫肽携带的辅助表位通过提供 CD4 帮助在这些 HLA 类型内拓宽应答，但不能消除 HLA 限制本身。未开发 HLA 无限制的处方。
• The myelodysplastic syndrome indication is the programme's origin point, because WT1 is expressed in the leukaemic blasts of most acute myeloid leukaemia and myelodysplastic syndrome cases and because azacitidine failure leaves patients with poor options. The vaccine's role there is consolidation or maintenance after failed hypomethylating therapy, aiming at the WT1-expressing clone rather than at bulk disease. The immune-response definition used in that study, delayed-type hypersensitivity or WT1-specific CD8 positivity, operationalizes success in a disease where tumour responses are hard to measure. No regimen beyond the intradermal schedule has been studied in that population.骨髓增生异常综合征适应症是项目的起点，因为 WT1 在多数急性髓系白血病与骨髓增生异常综合征病例的白血病母细胞中表达，且阿扎胞苷失败后患者选择恶劣。该疫苗在那里的角色是失败去甲基化治疗后的巩固或维持，针对表达 WT1 的克隆而非大部分疾病。该研究使用的免疫反应定义（延迟型超敏或 WT1 特异性 CD8 阳性）在一个肿瘤缓解难以测量的疾病中把成功操作化。该人群中未研究皮内方案之外的给药方案。
• The glioblastoma indication tests a different logic: rather than consolidation after remission, the vaccine is combined with bevacizumab in recurrent or progressive disease after resection, where anti-angiogenic therapy controls oedema and the vaccine attacks WT1-expressing tumour cells. The bevacizumab schedule of 10 mg/kg every two weeks provides the backbone against which vaccine-induced immunity is measured. Earlier phase work in this population reported no dose-limiting toxicities and higher induction of WT1-specific cytotoxic lymphocytes, which justified the phase 3 commitment. No other solid tumour indication has entered the clinic for DSP-7888 Emulsion.胶质母细胞瘤适应症检验的是不同逻辑：疫苗不是在缓解后巩固，而是在切除术后复发或进展疾病中与贝伐珠单抗联用，抗血管生成治疗控制水肿、疫苗攻击表达 WT1 的肿瘤细胞。每两周 10 mg/kg 的贝伐珠单抗方案提供了衡量疫苗诱导免疫的骨干。该人群中早期研究无剂量限制毒性且更高水平诱导 WT1 特异性细胞毒性淋巴细胞，这证明了 3 期投入的合理性。DSP-7888 乳剂尚无其他实体瘤适应症进入临床。
• No pediatric, geriatric-specific or organ-impairment dosing has been defined for adegramotide, and both trial populations are adults with defined performance status. The intradermal route requires trained administration and produces delayed-type hypersensitivity reactions that are read as part of the immune assessment rather than as adverse events. Whether the vaccine can be combined with hypomethylating agents or chemotherapy in the same patient has not been systematically studied, and the phase 3 glioblastoma design deliberately pairs it with an anti-angiogenic antibody instead. Any statement about efficacy remains preliminary, and no tumor-response rate has been published for the vaccine in either setting.阿德格拉莫肽未定义儿童、老年特异或器官受损给药，两个试验人群均为具有限定体能状态的成人。皮内途径需要受过训练的给药，其产生的延迟型超敏反应作为免疫评估的一部分判读而非不良事件。该疫苗能否在同一患者中与去甲基化药物或化疗联用未经系统研究，3 期胶质母细胞瘤设计刻意让其与抗血管生成抗体配对。任何疗效表述均为初步，两种情境下均未公布该疫苗的肿瘤缓解率。

Adverse effects

• The tolerability record for DSP-7888 Emulsion is favourable at the level of published summaries: in the completed myelodysplastic syndrome study the treatment was well tolerated, and in glioblastoma it was well tolerated with no dose-limiting toxicities. The dominant expected events are injection-site reactions from the intradermal emulsion, a class feature of Montanide-formulated peptide vaccines, together with delayed-type hypersensitivity responses that in this programme are counted as evidence of immunization. No grade distribution, no rate table and no serious-adverse-event breakdown has been published for either study, so the compound's formal safety profile is incompletely characterized in the public record. No treatment-related death has been reported for the vaccine.DSP-7888 乳剂的耐受记录在已发表摘要层面是有利的：在已完成的骨髓增生异常综合征研究中治疗耐受良好，在胶质母细胞瘤中耐受良好且无剂量限制毒性。预期的主要事件是皮内乳剂引起的注射部位反应（Montanide 处方肽疫苗的类内特征），以及延迟型超敏反应——后者在本项目中被计为免疫接种的证据。两项研究均未发表分级分布、发生率表或严重不良事件细分，因此该化合物的正式安全性特征在公开记录中刻画不全。未报告该疫苗的治疗相关死亡。
• The immune reactions that define success are themselves the main tolerability consideration: 78.7 percent of myelodysplastic syndrome patients had a positive WT1-specific immune reaction, and delayed-type hypersensitivity reactions at the injection site are part of that assessment. Local reactions are expected to be frequent with a depot emulsion given repeatedly over months, and they are managed as a feature of the formulation rather than as toxicity. Systemic reactogenicity of the kind seen with some adjuvanted vaccines has not been highlighted in the published summaries. The every-four-week maintenance schedule limits cumulative local exposure compared with more frequent regimens.定义成功的免疫反应本身是主要耐受性考量：78.7% 的骨髓增生异常综合征患者出现阳性 WT1 特异性免疫反应，注射部位的延迟型超敏反应是该评估的一部分。储库乳剂数月重复给药，局部反应预期频繁，按处方特征而非毒性管理。某些佐剂疫苗所见的那种全身反应原性在已发表摘要中未被强调。每四周的维持方案与其他更频繁的方案相比限制了累积局部暴露。
• A theoretical safety concern for any WT1-directed therapy is autoimmunity, because WT1 is expressed in normal adult kidney and gonadal tissue, so breaking tolerance could in principle produce renal or reproductive autoimmune injury. No such syndrome has been reported for DSP-7888 Emulsion, and the clinical experience to date has not identified kidney or gonad toxicity attributable to the vaccine. The helper T-cell component, adegramotide, broadens the response against WT1 and could in principle increase that risk relative to a CD8-only vaccine, but no comparative safety data exist. Trial protocols monitor renal function and general autoimmune events under standard rules.任何 WT1 靶向治疗的理论安全性关切是自身免疫，因为 WT1 在正常成人肾与性腺组织中表达，因此打破耐受原则上可产生肾或生殖自身免疫损伤。DSP-7888 乳剂未报告此类综合征，迄今临床经验未发现归因于该疫苗的肾或性腺毒性。辅助性 T 细胞组分阿德格拉莫肽拓宽了抗 WT1 应答，原则上相对于仅含 CD8 的疫苗可能增加该风险，但无比较安全性数据。试验方案按标准规则监测肾功能与一般自身免疫事件。
• Because the vaccine is given intradermally, patients with skin conditions at injection sites or with bleeding tendencies from prior therapy are managed under protocol rules rather than under label guidance. In myelodysplastic syndrome the baseline cytopenias complicate attribution of haematologic events, and the trial's laboratory thresholds govern eligibility. No maximal tolerated dose has been reported for the vaccine in either study, consistent with a well-tolerated profile at the studied doses. The absence of dose-limiting toxicity in glioblastoma was one of the findings that justified phase 3 advancement.由于疫苗皮内给药，注射部位皮肤病或既往治疗出血倾向的患者按方案规则管理而非标签指导。在骨髓增生异常综合征中，基线血细胞减少使血液学事件归因复杂，试验的实验室界值管辖合格性。两项研究均未报告该疫苗的最大耐受剂量，与所研究剂量下耐受良好的特征一致。胶质母细胞瘤中无剂量限制毒性是证明 3 期推进合理性的发现之一。
• Interaction liability is minimal by design: a peptide emulsion has no cytochrome metabolism and no classical pharmacokinetic interactions, and the programme's combination with bevacizumab is immunological rather than metabolic. Whether the vaccine's immune stimulation alters the safety of concurrent agents has not been formally studied, and the glioblastoma protocol manages co-medications under standard rules. No food or beverage interaction exists for an intradermal vaccine. The main practical interaction risk is immunological, namely that concurrent immunosuppressive therapy could blunt the vaccine response, which is why hypomethylating agents were not combined in the same study.相互作用风险按设计极小：肽乳剂无细胞色素代谢、无经典药代动力学相互作用，该项目与贝伐珠单抗的联合是免疫学而非代谢性的。疫苗的免疫刺激会否改变合并药物的安全性未经正式研究，胶质母细胞瘤方案按标准规则管理合并用药。皮内疫苗不存在食物或饮料相互作用。主要的实际相互作用风险是免疫学性的，即合并免疫抑制治疗可能钝化疫苗应答，这就是去甲基化药物未在同一研究中联用的原因。

Contraindications and interactions

• No contraindications were established for adegramotide, because the compound never received a marketing authorization and the clinical protocols defined eligibility criteria rather than label contraindications. The practical boundaries are the HLA restriction, since only HLA-A02:01, HLA-A02:06 and HLA-A24:02 carriers present the vaccine epitopes, and the disease settings, namely azacitidine-failed higher-risk myelodysplastic syndrome and recurrent glioblastoma after resection. Patients must be able to receive repeated intradermal injections over many months. Performance-status and organ-function thresholds in the protocols function as the operative limits, and they have not been published in detail.阿德格拉莫肽未确立禁忌，因为该化合物从未获得上市许可，临床方案定义的是合格标准而非标签禁忌。实际边界是 HLA 限制——只有 HLA-A02:01、HLA-A02:06 与 HLA-A24:02 携带者呈递疫苗表位，以及疾病情境，即阿扎胞苷失败的高危骨髓增生异常综合征与切除术后复发胶质母细胞瘤。患者须能接受数月内反复皮内注射。方案中的体能状态与器官功能界值起实际限制作用，其细节未详细公布。
• Interaction management in the programme is dominated by immunological rather than metabolic considerations. The deliberate decision not to combine the vaccine with hypomethylating agents reflects the concern that myelosuppressive or immunosuppressive therapy would blunt the intended T-cell response, not a specific drug-interaction finding. The glioblastoma combination with bevacizumab was chosen because anti-angiogenic therapy is not broadly immunosuppressive and because the two mechanisms are complementary. No cytochrome-mediated interaction is expected from a peptide vaccine, and none has been reported. Concurrent immunosuppressants, including corticosteroids at immunosuppressive doses, would be expected to reduce vaccine immunogenicity as a matter of pharmacology.该项目中的相互作用管理由免疫学而非代谢性考量主导。刻意不让疫苗与去甲基化药物联用，反映的是担心骨髓抑制或免疫抑制治疗会钝化预期 T 细胞应答，而非具体的药物相互作用发现。选择与贝伐珠单抗联用于胶质母细胞瘤，是因为抗血管生成治疗不具广泛免疫抑制性且两种机制互补。肽疫苗不预期有细胞色素介导的相互作用，亦无报告。合并免疫抑制剂（包括免疫抑制剂量的皮质类固醇）按药理学常识预期会降低疫苗免疫原性。
• The autoimmune contraindication category is theoretical for WT1 vaccines, given normal-tissue expression in kidney and gonads, but no clinical autoimmune signal has emerged in either study, and no protocol-level autoimmune exclusion has been reported. Patients with active autoimmune disease were not specifically described in the published eligibility criteria, and the trial experience provides no basis for a contraindication statement. Pregnancy and lactation were not studied, and vaccination in those settings would not be expected. As with other intradermal products, injection-site skin disease is a practical barrier to administration rather than a formal contraindication.鉴于 WT1 在肾与性腺的正常组织表达，自身免疫禁忌类别对 WT1 疫苗是理论性的，但两项研究均未出现临床自身免疫信号，亦未报告方案级自身免疫排除。已发表合格标准未具体描述活动性自身免疫病患者，试验经验不提供禁忌声明的基础。妊娠与哺乳未予研究，这些情境下的接种亦不预期。与其他皮内制品一样，注射部位皮肤病是给药的实际障碍而非正式禁忌。

Pharmacology

• The pharmacology of adegramotide is that of a CD4-positive T-cell epitope: after intradermal injection, the peptide is taken up by antigen-presenting cells at the vaccination site, carried to nearby lymph nodes, processed and presented on HLA class II molecules, activating WT1-specific helper T cells. The activated CD4 cells then support the cytotoxic arm, augmenting CD8-positive T-cell numbers and enabling the cytotoxic lymphocytes induced by the companion peptide （nelatimotide） to function inside the immunosuppressive tumour microenvironment. Preclinical comparison was explicit: CD8 cells induced by （nelatimotide） alone did not become activated against tumour cells, even with anti-PD-1, whereas CD8 cells induced by the complete emulsion did. Adegramotide is the component that closes that gap.阿德格拉莫肽的药理学是 CD4 阳性 T 细胞表位的药理学：皮内注射后，肽在接种部位被抗原呈递细胞摄取，带至附近淋巴结，加工并呈递于 HLA II 类分子，激活 WT1 特异性辅助性 T 细胞。激活的 CD4 细胞随后支持细胞毒性臂，增加 CD8 阳性 T 细胞数量，并使伴随多肽 （nelatimotide） 诱导的细胞毒性淋巴细胞能在免疫抑制性肿瘤微环境中发挥作用。临床前比较很明确：仅 （nelatimotide） 诱导的 CD8 细胞对肿瘤细胞不激活，即使有抗 PD-1 也是如此，而完整乳剂诱导的 CD8 细胞却能。阿德格拉莫肽正是弥合这一缺口的组分。
• WT1 itself is a zinc-finger transcription factor overexpressed in the tumours under study, and the vaccine's epitopes are drawn from its sequence, so the response is against a shared self-antigen rather than a patient-specific neoepitope. The embedded CD8 epitope within adegramotide means that the helper peptide can also contribute directly to the cytotoxic response, which the developers demonstrated experimentally. Once activated, WT1-specific CD4 and CD8 cells migrate to the tumour microenvironment, where they attack WT1-positive cancer cells. The antitumour effect is therefore cellular and antigen-specific rather than antibody-mediated, which distinguishes the programme from the earlier anti-idiotype vaccine approach to ovarian cancer.WT1 本身是一种锌指转录因子，在所研究肿瘤中过表达，疫苗表位取自其序列，因此应答针对共享自身抗原而非患者特异新表位。阿德格拉莫肽内嵌的 CD8 表位意味着辅助肽也能直接贡献于细胞毒性应答，开发者在实验中证明了这一点。一旦激活，WT1 特异性 CD4 与 CD8 细胞迁移至肿瘤微环境，攻击 WT1 阳性癌细胞。因此抗肿瘤效应是细胞性且抗原特异的，而非抗体介导的，这将该项目与早期卵巢癌抗独特型疫苗方法区分开来。
• The clinical correlate of the mechanism is the immune-reaction definition used in the myelodysplastic syndrome study: 78.7 percent of patients had a delayed-type hypersensitivity response or WT1-specific CD8-positive T-cell positivity, and those with a positive reaction survived significantly longer than those without. That association is correlative, since immune responders may differ systematically from non-responders, but it is the kind of pharmacodynamic signal that vaccine programmes use to justify advancement. In glioblastoma the corresponding readout is the level of WT1-specific cytotoxic lymphocyte induction, which was higher in vaccinated patients. Neither study has published a validated pharmacodynamic marker for dose selection.该机制的临床对应物是骨髓增生异常综合征研究使用的免疫反应定义：78.7% 的患者有延迟型超敏反应或 WT1 特异性 CD8 阳性 T 细胞，阳性反应者生存显著长于无反应者。该关联是相关性的，因为免疫应答者可能系统性地区别于无应答者，但它是疫苗项目用来证明推进合理性的那类药效学信号。在胶质母细胞瘤中，对应读数是 WT1 特异性细胞毒性淋巴细胞诱导水平，接种患者中更高。两项研究均未发表经验证的剂量选择药效学标志物。
• The adjuvant pharmacology is inseparable from the peptide pharmacology: Montanide ISA 51 VG, the water-in-oil adjuvant in DSP-7888 Emulsion, stabilizes the vaccine peptides and slows their systemic release, allowing time for dendritic cells and macrophages to arrive at the injection site and absorb antigen. The developers note that this depot effect can have the unintended consequence of trapping cytotoxic T cells at the vaccination site, and that delivering longer peptides, such as the 19-amino-acid （nelatimotide） and the 18-amino-acid adegramotide, rather than shorter 9-amino-acid sequences, mitigates that capture. The peptide lengths and the adjuvant are therefore a single pharmacological system, not independent choices.佐剂药理学与肽药理学不可分割：DSP-7888 乳剂中的水油佐剂 Montanide ISA 51 VG 稳定疫苗肽并减缓其系统释放，让树突状细胞与巨噬细胞有时间抵达注射部位并摄取抗原。开发者指出，该储库效应可能有一个非预期后果——把细胞毒性 T 细胞困在接种部位，而递送较长肽段（如 19 氨基酸的 （nelatimotide） 与 18 氨基酸的阿德格拉莫肽）而非较短 9 氨基酸序列，可缓解这种捕获。因此肽长与佐剂是单一药理系统，而非独立选择。
• Combination pharmacology with checkpoint blockade is the programme's second theme: preclinical work showed that anti-PD-1 and DSP-7888 Emulsion enhance each other's antitumour effects, with the combination restoring activation of cytotoxic lymphocytes that the vaccine alone left quiescent. The proposed mechanism is that vaccines generating strong T-cell immunity meet a checkpoint-inhibited tumour microenvironment that no longer suppresses them. Clinical trials of DSP-7888 Emulsion in combination with anti-PD-1 antibodies, including nivolumab or pembrolizumab, have been reported as underway. No published combination efficacy data exist, and the phase 3 glioblastoma study pairs the vaccine with bevacizumab rather than with a checkpoint inhibitor.与检查点阻断的联合药理学是该项目的第二主题：临床前工作显示抗 PD-1 与 DSP-7888 乳剂相互增强抗肿瘤效应，联合可恢复疫苗单独作用下静止的细胞毒性淋巴细胞活性。提议机制是产生强 T 细胞免疫的疫苗，遇到了不再抑制它们的检查点抑制性肿瘤微环境。DSP-7888 乳剂与抗 PD-1 抗体（包括纳武利尤单抗或帕博利珠单抗）联用的临床试验已被报道在进行中。无已发表联合疗效数据，3 期胶质母细胞瘤研究让疫苗与贝伐珠单抗而非检查点抑制剂配对。
• As a peptide vaccine, adegramotide has no conventional pharmacokinetics: absorption, distribution, metabolism and excretion parameters do not apply in the small-molecule sense, and the pharmacological exposure is the immune response itself. The dosing schedule, weekly for five doses then fortnightly and monthly, is designed to prime and then maintain the T-cell response rather than to sustain a plasma concentration. No half-life, bioavailability or metabolism data exist, and none would be meaningful for the peptide in this context. The effective dose is therefore defined immunologically, by the induction of WT1-specific T cells, rather than by exposure metrics.作为肽疫苗，阿德格拉莫肽没有经典药代动力学：吸收、分布、代谢与排泄参数不适用于小分子意义上的描述，药理暴露就是免疫应答本身。给药方案（前五剂每周、随后双周与每月）旨在启动并维持 T 细胞应答，而非维持血浆浓度。不存在半衰期、生物利用度或代谢数据，在此情境下对肽而言也无意义。因此有效剂量由免疫学定义，即 WT1 特异性 T 细胞的诱导，而非暴露指标。

Chemistry

• Adegramotide is a synthetic linear peptide of 18 amino acids, a WT1-derived CD4-positive T-cell epitope with an embedded CD8 epitope, and it is catalogued under CAS number 1252802-98-4, PubChem CID 121488164, ChemSpider ID 59651405, UNII 4XQ7W02EQ0, KEGG drug number D11057, DrugBank identifier DB17248, ChEMBL identifier CHEMBL3989952 and Wikidata item Q48997033. Its molecular formula is C87H123N19O24, with InChIKey QMUKFZMAYHSADK-MZDDNWLQSA-N, and the database IUPAC name records the full sequence as a chain of standard L-amino-acid residues beginning with tryptophan and ending with leucine. As a peptide vaccine component it is manufactured synthetically rather than recombinantly, which simplifies production relative to protein therapeutics.阿德格拉莫肽是一种 18 个氨基酸的合成线性肽，WT1 衍生的 CD4 阳性 T 细胞表位，内嵌 CD8 表位，收录编号为 CAS 1252802-98-4、PubChem CID 121488164、ChemSpider 59651405、UNII 4XQ7W02EQ0、KEGG 药物编号 D11057、DrugBank DB17248、ChEMBL CHEMBL3989952 与 Wikidata Q48997033。其分子式为 C87H123N19O24，InChIKey 为 QMUKFZMAYHSADK-MZDDNWLQSA-N，数据库 IUPAC 名以标准 L-氨基酸残基链记录全序列，以色氨酸开头、亮氨酸结尾。作为肽疫苗组分，它以合成而非重组方式生产，相对蛋白治疗药物简化了制造。
• The formulation is as important as the molecule: DSP-7888 Emulsion combines the two peptides in Montanide ISA 51 VG, a water-in-oil adjuvant from Seppic that is widely used in therapeutic cancer vaccines. The emulsion stabilizes the peptides, slows their release and creates the depot that recruits antigen-presenting cells to the injection site. Administration is intradermal, which places the antigen where dendritic cells are dense, and the schedule escalates from weekly to fortnightly to monthly injections as the response is established. No other excipient or formulation detail has been published for the clinical material, and the emulsion is prepared fresh per dose rather than supplied as a ready-to-use suspension.处方与分子同等重要：DSP-7888 乳剂在 Montanide ISA 51 VG（Seppic 出品、广泛用于治疗性癌症疫苗的水油佐剂）中组合两种多肽。该乳剂稳定肽段、减缓释放，并形成招募抗原呈递细胞至注射部位的储库。给药为皮内，把抗原置于树突状细胞密集之处，方案随应答建立从每周升级到双周再到每月注射。临床材料未发表其他辅料或处方细节，该乳剂按剂新制而非以即用混悬液供应。
• The companion peptide （nelatimotide）, 19 amino acids and carrying two WT1-specific CD8 epitopes, is the cytotoxic arm of the pair, and the two peptides are formulated together in a fixed combination. Their division of labour, CD8 killing versus CD4 help, was established preclinically and is the design core of the emulsion. Neither peptide is developed as a stand-alone vaccine, and the fixed combination is the only clinical form. The peptide sequences are drawn from WT1's zinc-finger region, the part of the protein that carries the immunogenic epitopes used across the WT1 vaccine field. No modified, elongated or conjugated analogue of adegramotide has been reported.伴随多肽 （nelatimotide） 为 19 个氨基酸、携带两个 WT1 特异性 CD8 表位，是该配对的细胞毒性臂，两条肽以固定组合共同处方。它们的分工（CD8 杀伤对 CD4 帮助）经临床前确立，是乳剂的设计核心。两条肽均未作为独立疫苗开发，固定组合是唯一临床形式。肽序列取自 WT1 的锌指区，即该蛋白携带 WT1 疫苗领域所用免疫原性表位的部分。未报道阿德格拉莫肽的修饰、延长或偶联类似物。
• As a synthetic peptide, adegramotide sits at the small end of the biologic size range, and its chemistry is fully described by sequence rather than by structural elaboration, with no glycosylation, no disulfide constraint and no conjugation in the clinical form. That simplicity is deliberate: peptide vaccines against shared self-antigens are easier to standardize than cell or protein vaccines, and the synthetic route avoids the variability of recombinant production. The compound's database records, including its KEGG and DrugBank entries, reflect its identity as a defined chemical entity rather than as a biologic mixture. No salt form or counterion specification has been published, as is normal for a freeze-dried peptide.作为合成肽，阿德格拉莫肽处于生物制品体积范围的小端，其化学由序列而非结构精细化充分描述，临床形式无糖基化、无二硫键约束、无偶联。这种简单是刻意的：靶向共享自身抗原的肽疫苗比细胞或蛋白疫苗更易标准化，合成路线避免重组生产的变异性。该化合物的数据库记录（包括 KEGG 与 DrugBank 条目）反映其作为定义明确化学实体而非生物混合物的身份。未发表盐型或抗衡离子规格，这对冻干肽属正常。

Society and culture

• Adegramotide has no regulatory status in any country, does not appear on the WHO Model List of Essential Medicines and has no ATC code, which is expected for an investigational vaccine component. Its development history places it in the second generation of therapeutic cancer vaccines, after the 2010 approval of sipuleucel-T demonstrated that a vaccine could improve survival in cancer, and alongside a field that includes WT1 peptide vaccines such as galinpepimut-S from other developers. The DSP-7888 programme is notable for its explicit two-arm peptide design, which addressed the helper-T-cell requirement that single-epitope vaccines had ignored. It is a frequently cited example of how peptide vaccine engineering responded to the failures of the first generation.阿德格拉莫肽在任何国家均无监管地位，未出现在 WHO 基本药物示范清单上，也没有 ATC 编码，这对在研疫苗组分属预期。其开发史把它置于治疗性癌症疫苗的第二代，即 sipuleucel-T 于 2010 年获批证明疫苗可改善癌症生存之后，也与包括其他开发者的 WT1 肽疫苗（如 galinpepimut-S）在内的领域并行。DSP-7888 项目以其明确的双臂肽设计著称，它解决了单表位疫苗一直忽视的辅助性 T 细胞需求。它是肽疫苗工程如何回应第一代失败的最常被引例子之一。
• The programme reflects the broader Japanese pharmaceutical presence in WT1 immunotherapy, a field in which Sumitomo's vaccine sits alongside academic and biotech efforts in Japan, Europe and the United States. WT1 vaccines have been among the most extensively studied shared-antigen vaccines in myelodysplastic syndrome and acute myeloid leukaemia, and the DSP-7888 studies are part of that evidence base. The choice of glioblastoma for the phase 3 programme extended the approach into solid tumours, where WT1 expression is documented but vaccine experience is thinner. No independent evaluation of the programme's prospects has been published, and no efficacy projection exists.该项目反映了日本制药业在 WT1 免疫治疗中的更广泛存在，在这一领域，住友的疫苗与日本、欧洲和美国的学术及生物技术努力并列。WT1 疫苗是骨髓增生异常综合征与急性髓系白血病中研究最充分的共享抗原疫苗之一，DSP-7888 研究是该证据基础的组成部分。3 期项目选择胶质母细胞瘤，把该方法扩展到实体瘤，那里 WT1 表达有记录但疫苗经验较薄。未发表对该项目前景的独立评价，亦无效疗效预测。
• The immune-response-associated survival difference in the myelodysplastic syndrome study, 78.7 percent of patients reacting and responders surviving longer, is the programme's most discussed data point, and it carries the same correlative caveat that has accompanied cancer vaccines since their first trials. Commentators have noted that the correlation is consistent with the vaccine working in responders and equally consistent with responders being patients with better baseline immune function. The glioblastoma phase 3 trial, with its 221 patients and bevacizumab backbone, is the study that will discriminate between those interpretations if it reports. Until then the programme's reputation rests on its immunogenicity rather than on demonstrated efficacy.骨髓增生异常综合征研究中免疫应答相关的生存差异（78.7% 的患者有反应、应答者生存更长）是该项目最受讨论的数据点，它带有自癌症疫苗首批试验以来就伴随的相关性告诫。评论者指出，该关联既与疫苗在应答者中起效一致，也同样与应答者基线免疫功能更好一致。入组 221 例、以贝伐珠单抗为骨干的胶质母细胞瘤 3 期试验，是若报告即可区分这两种解释的研究。在那之前，该项目的声誉立于其免疫原性而非已证明的疗效。
• Within the targeted-protein and peptide-therapy literature, DSP-7888 Emulsion is presented as a mechanistic case study in how adjuvant and peptide length choices shape vaccine outcomes, and its mechanism paper is the standard citation for the CTL-trapping argument. The two-peptide design has influenced subsequent shared-antigen vaccine programmes, which increasingly include helper epitopes alongside cytotoxic ones. For the wider public the compound is invisible, and no patient advocacy group or media franchise surrounds it. Its cultural footprint is confined to oncology and immunology professional discourse, where it serves as a reference for rational peptide vaccine design.在靶向蛋白与肽疗法文献中，DSP-7888 乳剂作为佐剂与肽长选择如何塑造疫苗结果的机制案例呈现，其机制论文是 CTL 捕获论证的标准引用。双肽设计影响了后续共享抗原疫苗项目，后者越来越多地在细胞毒性表位旁纳入辅助表位。对更广义的公众而言该化合物不可见，没有患者倡导团体或媒体品牌围绕它。其文化足迹限于肿瘤学与免疫学专业论述，在那里它充当理性肽疫苗设计的参照。

Availability and economics

• Adegramotide is not commercially available anywhere and is supplied only through the DSP-7888 Emulsion clinical programme, which comprises a completed phase 1/2 study in higher-risk myelodysplastic syndrome and a phase 3 study in recurrent glioblastoma. There is no list price, no reimbursement status and no generic or biosimilar landscape, because no market authorization exists. Access is limited to trial participants at the participating centres, and the phase 3 study's planned enrolment of 221 patients caps the exposed population in the current programme. No expanded-access or compassionate-use pathway exists for the vaccine.阿德格拉莫肽在任何地方均无商业供应，仅通过 DSP-7888 乳剂临床项目提供，该项目包括一项已完成的高危骨髓增生异常综合征 1/2 期研究与一项复发胶质母细胞瘤 3 期研究。不存在市场许可，因此没有挂牌价格、没有报销状态，也没有仿制药或生物类似药格局。可及性限于参与中心的试验受试者，3 期研究 221 例的计划入组限制了当前项目中的暴露人群。该疫苗不存在扩大可及或同情使用途径。
• No pricing, cost-effectiveness or health-technology-assessment data exist for adegramotide, and none can exist before an approval decision. Development costs are carried by Sumitomo Pharma, which designed the two-peptide emulsion and ran both the haematological and neuro-oncology programmes. The economics of a fixed-combination peptide vaccine are dominated by manufacturing and clinical-trial costs rather than by API cost, and the synthetic peptide route keeps the production burden modest relative to cell therapies. No licensing, partnership or milestone terms have been disclosed. The programme's commercial case would rest on the phase 3 glioblastoma result, which had not been reported as of the latest updates.阿德格拉莫肽不存在定价、成本效果或卫生技术评估数据，在获批决定前也不可能存在。开发成本由住友制药承担，该公司设计了双肽乳剂并运营血液学与神经肿瘤两个项目。固定组合肽疫苗的经济性由生产与临床试验成本主导而非 API 成本，合成肽路线相对细胞疗法保持较低生产负担。未披露许可、合作或里程碑条款。该项目的商业案例立于 3 期胶质母细胞瘤结果，截至最新更新尚未报告。
• The myelodysplastic syndrome study is complete, and its data are the programme's principal asset: a well-tolerated vaccine with a high immune-reaction rate and a survival association in responders. Whether that translates into a registrational programme in azacitidine-failed disease depends on the sponsor's strategy, and no further study in that indication has been registered publicly. The glioblastoma phase 3 study represents the larger commitment and the larger risk, combining the vaccine with bevacizumab in a disease where previous vaccine efforts have disappointed. For patients in either setting, access today means enrolment in a trial, principally at academic centres.骨髓增生异常综合征研究已完成，其数据是该项目的主要资产：一种耐受良好、免疫反应率高、应答者有生存关联的疫苗。它能否转化为阿扎胞苷失败疾病中的注册项目取决于申办方策略，该适应症尚未公开注册后续研究。胶质母细胞瘤 3 期研究代表更大的投入与更大的风险，在该疾病中把疫苗与贝伐珠单抗联用，而此前的疫苗努力令人失望。对两种情境中的患者而言，当今的可及性意味着入组试验，主要在研究型中心。
• The WT1 vaccine field provides the competitive context: other WT1 peptide vaccines have been tested in myelodysplastic syndrome and acute myeloid leukaemia, and the shared-antigen approach competes with neoepitope vaccines, cell therapies and checkpoint blockade for the same patients. A successful DSP-7888 result would validate the two-peptide design and the long-peptide depot logic for the whole field, while failure would reinforce the pattern of immunogenicity without benefit that has marked shared-antigen vaccines. No head-to-head comparison between WT1 vaccines has been conducted. For now, adegramotide's availability is that of an investigational peptide inside a fixed combination, known to patients only through trial participation.WT1 疫苗领域提供了竞争背景：其他 WT1 肽疫苗已在骨髓增生异常综合征与急性髓系白血病中测试，共享抗原方法与新表位疫苗、细胞疗法及检查点阻断争夺同一患者群。DSP-7888 的成功结果将验证双肽设计与长肽储库逻辑对整个领域的价值，失败则会强化共享抗原疫苗标志性的「有免疫原性而无获益」模式。WT1 疫苗之间未进行头对头比较。目前，阿德格拉莫肽的可及性是固定组合中在研肽的可及性，患者仅通过试验参与知晓它。